Biogen

CEO Chris Viehbacher has reoriented Biogen toward cash discipline and pipeline breadth after a difficult period. 2025 execution featured Alzheimer’s access expansions with Eisai, cost control progress, and portfolio building in lupus and immunology.

Governance around capital has been more measured, and guidance language has been consistent about MS pressure while emphasizing launch products. That said, the organization must still prove it can scale Leqembi sustainably, navigate SMA dose-regulatory feedback, and deliver clean Phase 3 lupus/immunology results.

Overall we see a competent team with credible operating focus but not yet a demonstrably superior allocator track record.